Biotrial x Parean Strengthened Partnership

Biotrial and Parean strengthen their partnership to expand Preclinical and Clinical capabilities.

Already collaborating on the development of a novel preclinical lung cancer model combining a controlled microbiome, a humanized immune system, and tumor cells derived from patients (MESHCAP project), Biotrial and Parean are expanding their collaboration to support the development of immunotherapies, cell therapies, and vaccines in oncology and autoimmune diseases.

Through this partnership, Biotrial will leverage Parean’s expertise in immunology bioassays, single-cell omics, and omics-driven data science, offering sponsors a comprehensive and translational approach.

This strengthened collaboration brings expertise in:

• Non-clinical development, including target scoring, new modality characterization, and TCR lead generation
• Clinical studies, with advanced cell therapy characterization and high-content readouts
• Biometrics and Data Science services
• Bioanalytical services

About Biotrial: Founded in 1989, Biotrial, leading full service CRO, provides solutions from preclinical to clinical studies, bringing a wealth of expertise to the study feasibility and design process. Biotrial’s services are available as full services or stand-alone contracts including: Preclinical Pharmacology, Clinical Development, Data Management, Core Lab services with EEG & ECG, imaging, Data Science and Bioanalysis.

About Parean Biotechnologies: Parean Biotechnologies specializes in advanced immunology and omics technologies, including immunology bioassays, single-cell omics, and data science. The company supports the development of innovative therapies, particularly in oncology and autoimmune diseases, through cutting-edge scientific expertise.